Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Trial Evaluating Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
his study will test whether giving dexamethasone through a vein can improve pain control after total hip replacement surgery. Dexamethasone is commonly used to reduce nausea and may also help with pain, but it is not clear which dose works best. Patients will be randomly assigned to receive either no dexamethasone, 4 mg, or 8 mg, in addition to standard anesthesia and a nerve block (PENG block). The main goal is to see how long patients go without needing additional pain medication after surgery. The study will also look at pain levels, use of opioid painkillers, nausea and vomiting, blood sugar levels, and possible side effects.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Effective pain control after total hip arthroplasty (THA) remains a key component of perioperative care, as inadequate analgesia may delay mobilization, prolong hospital stay, and increase the need for opioids. Regional anesthesia techniques, such as the pericapsular nerve group (PENG) block, are increasingly used to improve postoperative pain management while preserving motor function.
Dexamethasone administered intravenously is commonly used in perioperative care, primarily for the prevention of postoperative nausea and vomiting. In addition, it has been shown to prolong the duration of analgesia when used as an adjunct to regional anesthesia. However, there is still uncertainty regarding the optimal intravenous dose that provides clinically meaningful analgesic benefit without increasing the risk of adverse effects, particularly hyperglycemia.
Previous studies have typically used doses ranging from 4 mg to 8 mg, but direct comparisons between these doses, as well as comparison with placebo, remain limited in patients undergoing THA. Furthermore, the potential dose-response relationship of intravenous dexamethasone in this specific surgical population has not been clearly established.
This study is designed to address this knowledge gap by evaluating whether intravenous dexamethasone provides additional analgesic benefit in patients undergoing THA with PENG block, and whether higher doses result in improved outcomes compared to lower doses or no dexamethasone. The findings may help optimize perioperative analgesic strategies and support more evidence-based dosing of dexamethasone in orthopedic surgery.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Małgorzata Reysner, MD PhD
- Telefonnummer: +48 (61) 8310122
- E-mail: mreysner@ump.edu.pl
Undersøgelse Kontakt Backup
- Navn: Tomasz Reysner, MD PhD
- Telefonnummer: +48 (61) 8310122
- E-mail: mreysner@ump.edu.pl
Studiesteder
-
-
-
Poznan, Polen, 62-701
- Rekruttering
- Poznan University of Medical Sciences
-
Kontakt:
- Malgorzata Reysner, M.D. Ph.D.
- Telefonnummer: +48 61 873 83 03
- E-mail: mreysner@ump.edu.pl
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years
- Scheduled for elective total hip arthroplasty (THA)
- Planned use of regional anesthesia including PENG block
- American Society of Anesthesiologists (ASA) physical status I-III
- Ability to understand the study procedures and provide written informed consent
- Ability to assess pain using the Numeric Rating Scale (NRS)
Exclusion Criteria:
- Known hypersensitivity to dexamethasone or any component of the study medication
- Chronic corticosteroid therapy or use of systemic steroids within 14 days prior to surgery
- Active systemic infection or sepsis
- Significant immunosuppression (e.g., chemotherapy, biological therapy)
- Pregnancy or breastfeeding
- Severe cognitive impairment or inability to reliably assess pain
- Uncontrolled diabetes mellitus (e.g., HbA1c > 8.5% or baseline blood glucose > 200 mg/dL)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo (0 mg Intravenous Dexamethasone)
Participants receive placebo (0.9% sodium chloride) administered intravenously in a volume identical to active treatment after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous administration of 0.9% sodium chloride in a volume identical to active treatment, given after induction of anesthesia.
Andre navne:
|
|
Aktiv komparator: Dexamethasone 4 mg Intravenous
Participants receive 4 mg dexamethasone administered intravenously after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 4 mg
Andre navne:
|
|
Aktiv komparator: Dexamethasone 8 mg Intravenous
Participants receive 8 mg dexamethasone administered intravenously after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 8 mg
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to First Rescue Analgesia
Tidsramme: 48 hours after surgery
|
Time from the end of surgery to the first administration of rescue analgesia (opioid) due to inadequate pain control (Numeric Rating Scale ≥ 4 or patient request). |
48 hours after surgery
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Postoperative Pain Intensity
Tidsramme: 6 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
6 hours after surgery
|
|
Postoperative Pain Intensity
Tidsramme: 12 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
12 hours after surgery
|
|
Postoperative Pain Intensity
Tidsramme: 24 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
24 hours after surgery
|
|
Postoperative Pain Intensity
Tidsramme: 48 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
48 hours after surgery
|
|
Opioid Consumption
Tidsramme: 48 hours after surgery
|
Total opioid consumption converted to morphine milligram equivalents (MME). |
48 hours after surgery
|
|
Opioid Consumption
Tidsramme: 24 hours after surgery
|
Total opioid consumption converted to morphine milligram equivalents (MME). |
24 hours after surgery
|
|
Incidence of Postoperative Nausea and Vomiting (PONV)
Tidsramme: 24 hours after surgery
|
Occurrence of nausea and/or vomiting and need for antiemetic treatment. |
24 hours after surgery
|
|
Blood Glucose Levels
Tidsramme: immidietly after surgery (0 hours after surgery)
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
immidietly after surgery (0 hours after surgery)
|
|
Blood Glucose Levels
Tidsramme: 6 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
6 hours after surgery
|
|
Blood Glucose Levels
Tidsramme: 12 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
12 hours after surgery
|
|
Blood Glucose Levels
Tidsramme: 24 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
24 hours after surgery
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Justyna Marszałek-Buko, MD, Poznan University of Medical Sciences
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Muskuloskeletale sygdomme
- Gigt
- Ledsygdomme
- Reumatiske sygdomme
- Slidgigt
- Slidgigt, Hofte
- Polycykliske forbindelser
- Uorganiske kemikalier
- Klorforbindelser
- Gravidier
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Steroider, fluoreret
- Gravideretrioler
- Natriumforbindelser
- Chlorider
- Hydrochlorsyre
- Dexamethason
- Dexamethason 21-phosphat
- Natriumchlorid
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 3/2026
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .